FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market

[News Reader]

Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. By June 8, 2009, Raptiva will no longer be available in the United States.

More... (http://www.fda.gov/bbs/topics/NEWS/2009/NEW01992.html)